Dong Bang Co Ltd, a Korean veterinary pharmaceutical manufacturer, will participate in the “Indo Livestock 2026 Expo & Forum,” which will be held in Jakarta, Indonesia, from June 16 to 18, as part of its global market expansion strategy.
Founded in 1983, Dong Bang Co Ltd has specialized in the production of veterinary pharmaceuticals for livestock and companion animals, including cattle, pigs, poultry, and pets. The company develops a wide range of products designed to support animal health and safe livestock production, including probiotics, hormones, antibiotics, pet anesthetics, and natural antiviral agents.
Through continuous R&D investment and global partnerships, the company has expanded its export presence across Southeast Asia, the Middle East, CIS countries, and Central Asia.
At the exhibition, Dong Bang Co Ltd plans to introduce its updated product lineup to existing overseas partners and potential buyers. The company will particularly highlight pet anesthetics, newly launched canine probiotics, and anti-inflammatory pain relief products, which are in high demand in Southeast Asian markets.
-
Launch: Moving to capture regional market momentum, the company finalized its presentation portfolio for the upcoming Indo Livestock 2026 Expo.
-
Portfolio Lineup: The expansion focuses heavily on high-demand, specialized veterinary therapeutics, including proprietary livestock reproductive hormones (for which Dong Bang holds exclusive in-house domestic production tech), newly formulated canine probiotics, specialized pet anesthetics, and targeted natural antiviral agents.
-
Strategic Shift: The move highlights a broader trend of East Asian pharmaceutical developers increasing their direct investments into Southeast Asian veterinary infrastructure to meet the booming regional demand for advanced pet care and biosecure livestock production.
